An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

A new thesis from Karolinska Institutet aims to advance our understanding of the bidirectional relationship between ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Our study thus confirmed what was found in people of African descent in the US: the genetic origin underpinning the excess ...

More than 1,000 genes may serve as possible treatment targets for individuals with kidney disease, according to a new study, ...

Nearly all children with ANCA-associated vasculitis demonstrate active kidney disease at diagnosis, and their renal function ...

Researchers have demonstrated the feasibility of a morphological-based approach to interpreting spatial transcriptomic (ST) data, helping to improve understanding of the lesions that occur in chronic ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Over 1,000 genes may serve as possible treatment targets for individuals with kidney disease, according to a new study. By creating the most complete and detailed genetic 'map' of kidney function to ...

Nate Robinson, the 11-year NBA veteran who won the league's Slam Dunk Contest three times, revealed on Instagram that he had ...